9,200 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Acquired by Galibier Capital Management Ltd.

Galibier Capital Management Ltd. bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 9,200 shares of the medical equipment provider’s stock, valued at approximately $993,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Crewe Advisors LLC purchased a new stake in Zimmer Biomet during the first quarter valued at about $31,000. Bangor Savings Bank purchased a new position in Zimmer Biomet during the third quarter valued at approximately $31,000. Family Firm Inc. acquired a new position in Zimmer Biomet in the 2nd quarter valued at approximately $33,000. J.Safra Asset Management Corp boosted its stake in shares of Zimmer Biomet by 712.1% during the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 235 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in shares of Zimmer Biomet during the 2nd quarter valued at $43,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of research reports. Oppenheimer reduced their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Royal Bank of Canada cut their price objective on shares of Zimmer Biomet from $130.00 to $120.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Raymond James cut their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Morgan Stanley reduced their target price on Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. Finally, Truist Financial restated a “hold” rating and issued a $112.00 price objective (down from $117.00) on shares of Zimmer Biomet in a research note on Friday, September 13th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $123.94.

Zimmer Biomet Price Performance

NYSE ZBH traded up $3.94 during trading on Wednesday, hitting $107.82. 165,564 shares of the company’s stock were exchanged, compared to its average volume of 1,471,784. The company has a current ratio of 1.29, a quick ratio of 0.63 and a debt-to-equity ratio of 0.31. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $101.47 and a fifty-two week high of $133.90. The company has a market cap of $22.18 billion, a PE ratio of 22.48, a P/E/G ratio of 1.88 and a beta of 1.02. The stock’s 50 day moving average price is $107.29 and its two-hundred day moving average price is $111.04.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.02. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. Zimmer Biomet’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.82 earnings per share. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.97 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.89%. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.